Literature DB >> 32003701

Angiotensin-Receptor Blockers and the Risk of Alzheimer´s Disease: A Meta-analysis.

Teodoro J Oscanoa1, José Amado1, Xavier Vidal2, Roman Romero-Ortuno3.   

Abstract

BACKGROUND: Anti-hypertensive medications may reduce the incidence of cognitive disorders. This may be due to reasons beyond their pure hypotensive effect. This study aimed to systematically review the association between the use of Angiotensin-Receptor Blockers (ARBs) and the incidence of Alzheimer's disease (AD).
METHODS: We systematically searched studies reporting the association between ARB use and the incidence of AD.
RESULTS: Ten studies (1 RCT, 2 case-control and 7 cohort studies) met the inclusion criteria. When all observational studies (9) were analyzed, ARB use was associated with a reduced risk of incident AD (HR 0.72, 95% CI: 0.58-0.88, p<0.001). In the only RCT, decrease in the incidence of AD was also significant (HR= 0.31, 95% CI: 0.14-0.68).
CONCLUSION: ARB use may reduce the risk of incident AD. This association does not imply causation and further research is required to clarify potential mechanisms. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Angiotensin-receptor blockers; alzheimer´s disease; angiotensin II; elderly; meta-analysis; pro-oxidant effects.

Mesh:

Substances:

Year:  2021        PMID: 32003701     DOI: 10.2174/1574884715666200131120224

Source DB:  PubMed          Journal:  Curr Rev Clin Exp Pharmacol        ISSN: 2772-4328


  4 in total

Review 1.  Brain angiotensin II and angiotensin IV receptors as potential Alzheimer's disease therapeutic targets.

Authors:  Jessika Royea; Edith Hamel
Journal:  Geroscience       Date:  2020-07-22       Impact factor: 7.713

Review 2.  Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease.

Authors:  Heeyoung Lee; EunYoung Kim
Journal:  Arch Pharm Res       Date:  2020-09-09       Impact factor: 4.946

3.  Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment.

Authors:  Ying Wang; Mingfei Li; Lewis E Kazis; Weiming Xia
Journal:  Alzheimers Dement       Date:  2022-04-04       Impact factor: 16.655

Review 4.  Brain Renin-Angiotensin System at the Intersect of Physical and Cognitive Frailty.

Authors:  Caglar Cosarderelioglu; Lolita S Nidadavolu; Claudene J George; Esther S Oh; David A Bennett; Jeremy D Walston; Peter M Abadir
Journal:  Front Neurosci       Date:  2020-09-30       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.